首页 > 最新文献

Cancer Causes & Control最新文献

英文 中文
Cancer history and accelerated aging: findings from a nationally representative sample in the US. 癌症史和加速衰老:来自美国全国代表性样本的研究结果。
IF 2.2 4区 医学 Q3 ONCOLOGY Pub Date : 2025-04-01 Epub Date: 2024-12-04 DOI: 10.1007/s10552-024-01941-w
Xuesong Han, Margaret Katana Ogongo, Feng Tian, Jingxuan Zhao, Zhiyuan Zheng, Zuyun Liu, K Robin Yabroff

Purpose: Cancer and its treatments may accelerate the aging process. However, accelerated aging among cancer survivors is not well understood. This study examines accelerated aging among adults with and without a cancer history in a nationally representative sample and identifies health-related social needs and behavioral factors associated with accelerated aging.

Methods: We conducted a cross-sectional study of 11,432 adults aged 20-84 years from the 1999 to 2010 National Health and Nutrition Examination Survey, including 728 cancer survivors. Accelerated aging was measured by validated Phenotypic Age Acceleration (PhenoAgeAccel) based on clinical chemistry biomarkers. We described accelerated aging by cancer history, demographics, health-related social needs, and health behaviors, and utilized weighted linear regression to assess their associations with accelerated aging.

Results: Majority of the sample were < 65 years old (n = 8,800, weighted percentage = 84.8%), female (n = 5,856, 50.8%), and non-Hispanic White (n = 5,709, 71.7%). Cancer survivors experienced an average of 0.14 (95% CI 0.03, 0.24) years of accelerated aging measured by PhenoAgeAccel. Individuals who were male, unmarried, less educated, with lower-income, or with 3 or more medical conditions also had accelerated aging regardless of cancer history. Moreover, health-related social needs in food insecurity, unemployment, health insurance and coverage continuity as well as obesity and smoking were associated with accelerated aging in both cancer survivors and individuals without a cancer history.

Conclusions:  Cancer survivors experience accelerated aging in the US. Addressing health-related social needs and promoting healthy behaviors in care delivery may advance healthy aging.

目的:癌症及其治疗可能加速衰老过程。然而,癌症幸存者中加速衰老的原因尚不清楚。本研究在全国代表性样本中检查了有和没有癌症病史的成年人的加速衰老,并确定了与加速衰老相关的健康相关的社会需求和行为因素。方法:我们对1999年至2010年全国健康与营养调查中11432名20-84岁的成年人进行了横断面研究,其中包括728名癌症幸存者。基于临床化学生物标志物,通过验证的表型年龄加速(PhenoAgeAccel)来测量加速衰老。我们通过癌症史、人口统计学、健康相关社会需求和健康行为来描述加速衰老,并利用加权线性回归来评估它们与加速衰老的关系。结论:在美国,癌症幸存者经历了加速衰老。解决与健康相关的社会需求和促进保健服务中的健康行为可以促进健康老龄化。
{"title":"Cancer history and accelerated aging: findings from a nationally representative sample in the US.","authors":"Xuesong Han, Margaret Katana Ogongo, Feng Tian, Jingxuan Zhao, Zhiyuan Zheng, Zuyun Liu, K Robin Yabroff","doi":"10.1007/s10552-024-01941-w","DOIUrl":"10.1007/s10552-024-01941-w","url":null,"abstract":"<p><strong>Purpose: </strong>Cancer and its treatments may accelerate the aging process. However, accelerated aging among cancer survivors is not well understood. This study examines accelerated aging among adults with and without a cancer history in a nationally representative sample and identifies health-related social needs and behavioral factors associated with accelerated aging.</p><p><strong>Methods: </strong>We conducted a cross-sectional study of 11,432 adults aged 20-84 years from the 1999 to 2010 National Health and Nutrition Examination Survey, including 728 cancer survivors. Accelerated aging was measured by validated Phenotypic Age Acceleration (PhenoAgeAccel) based on clinical chemistry biomarkers. We described accelerated aging by cancer history, demographics, health-related social needs, and health behaviors, and utilized weighted linear regression to assess their associations with accelerated aging.</p><p><strong>Results: </strong>Majority of the sample were < 65 years old (n = 8,800, weighted percentage = 84.8%), female (n = 5,856, 50.8%), and non-Hispanic White (n = 5,709, 71.7%). Cancer survivors experienced an average of 0.14 (95% CI 0.03, 0.24) years of accelerated aging measured by PhenoAgeAccel. Individuals who were male, unmarried, less educated, with lower-income, or with 3 or more medical conditions also had accelerated aging regardless of cancer history. Moreover, health-related social needs in food insecurity, unemployment, health insurance and coverage continuity as well as obesity and smoking were associated with accelerated aging in both cancer survivors and individuals without a cancer history.</p><p><strong>Conclusions: </strong> Cancer survivors experience accelerated aging in the US. Addressing health-related social needs and promoting healthy behaviors in care delivery may advance healthy aging.</p>","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":"379-388"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spatial patterns of colorectal cancer survival rates in Malaysia, 2013-2018. 2013-2018年马来西亚结直肠癌生存率的空间格局
IF 2.2 4区 医学 Q3 ONCOLOGY Pub Date : 2025-04-01 Epub Date: 2024-12-09 DOI: 10.1007/s10552-024-01945-6
Siti Ramizah Ramli, Zahir Izuan Azhar, Sukumaran Raman, Siti Norbayah Yusof, Mariam Mohamad

Background: Large geographical variations in colorectal cancer (CRC) survival rates have been reported across regions. Poorer survival rates were mainly found in socioeconomically deprived areas, highly dense areas, and areas lacking healthcare accessibility. The objective of this study was to identify, compare, and contrast the spatial patterns of 5-year CRC-specific survival rates and identify high-priority areas by districts in Malaysia.

Methods: This retrospective cohort study utilized secondary data from the National Cancer Registry. CRC patients (ICD10 C18-21) diagnosed between 2013 and 2018 were selected. Patient addresses were geocoded into districts and states via geospatial data from the National Geospatial Centre, whereas district population density data were gathered from the Population Census of Malaysia. Kaplan‒Meier survival analysis and log-rank test were conducted to determine and compare the 5-year CRC-specific survival rates, and the spatial distribution of CRC survival by district was determined via ArcGIS software.

Results: A total of 18,513 CRC patients were registered from 143 districts, with 10,819 deaths occurring during follow-up. The national 5-year CRC-specific survival rate was 42%, with median survival time of 36 months (95% CI: 34.46, 37.54). The eastern region (Kelantan, Terengganu, and Pahang) had the lowest survival (38.0%). Among the 143 districts, eighty-one (56.6%) reported survival rates below the national average while thirty-six (25.2%) were identified as high-priority districts.

Conclusion: The differences in CRC survival rates were evident according to geographical location. Area-based targeted interventions to improve CRC detection, management, and access to healthcare are imperative to address cancer survival disparities and help effectively allocate resources.

背景:据报道,不同地区结直肠癌(CRC)存活率存在较大的地理差异。生存率较低的地区主要是社会经济贫困地区、人口稠密地区和缺乏医疗服务的地区。本研究的目的是确定、比较和对比5年crc特异性生存率的空间格局,并确定马来西亚各区的高优先区域。方法:这项回顾性队列研究利用了国家癌症登记处的二手数据。选择2013 - 2018年诊断的CRC患者(ICD10 C18-21)。患者地址通过国家地理空间中心的地理空间数据被地理编码为地区和州,而地区人口密度数据则从马来西亚人口普查中收集。采用Kaplan-Meier生存分析和log-rank检验确定和比较5年CRC特异性生存率,并通过ArcGIS软件确定各地区CRC生存率的空间分布。结果:来自143个地区共登记了18513例结直肠癌患者,随访期间发生10819例死亡。全国5年crc特异性生存率为42%,中位生存时间为36个月(95% CI: 34.46, 37.54)。东部地区(吉兰丹、登嘉楼和彭亨州)的存活率最低(38.0%)。在143个地区中,81个(56.6%)报告的存活率低于全国平均水平,36个(25.2%)被确定为高优先区。结论:不同地区结直肠癌生存率差异明显。以地区为基础的有针对性的干预措施,以改善结直肠癌的检测、管理和获得医疗保健是解决癌症生存差异和帮助有效分配资源的必要条件。
{"title":"Spatial patterns of colorectal cancer survival rates in Malaysia, 2013-2018.","authors":"Siti Ramizah Ramli, Zahir Izuan Azhar, Sukumaran Raman, Siti Norbayah Yusof, Mariam Mohamad","doi":"10.1007/s10552-024-01945-6","DOIUrl":"10.1007/s10552-024-01945-6","url":null,"abstract":"<p><strong>Background: </strong>Large geographical variations in colorectal cancer (CRC) survival rates have been reported across regions. Poorer survival rates were mainly found in socioeconomically deprived areas, highly dense areas, and areas lacking healthcare accessibility. The objective of this study was to identify, compare, and contrast the spatial patterns of 5-year CRC-specific survival rates and identify high-priority areas by districts in Malaysia.</p><p><strong>Methods: </strong>This retrospective cohort study utilized secondary data from the National Cancer Registry. CRC patients (ICD10 C18-21) diagnosed between 2013 and 2018 were selected. Patient addresses were geocoded into districts and states via geospatial data from the National Geospatial Centre, whereas district population density data were gathered from the Population Census of Malaysia. Kaplan‒Meier survival analysis and log-rank test were conducted to determine and compare the 5-year CRC-specific survival rates, and the spatial distribution of CRC survival by district was determined via ArcGIS software.</p><p><strong>Results: </strong>A total of 18,513 CRC patients were registered from 143 districts, with 10,819 deaths occurring during follow-up. The national 5-year CRC-specific survival rate was 42%, with median survival time of 36 months (95% CI: 34.46, 37.54). The eastern region (Kelantan, Terengganu, and Pahang) had the lowest survival (38.0%). Among the 143 districts, eighty-one (56.6%) reported survival rates below the national average while thirty-six (25.2%) were identified as high-priority districts.</p><p><strong>Conclusion: </strong>The differences in CRC survival rates were evident according to geographical location. Area-based targeted interventions to improve CRC detection, management, and access to healthcare are imperative to address cancer survival disparities and help effectively allocate resources.</p>","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":"389-397"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unraveling the link between language barriers and cancer risk. 揭示语言障碍与癌症风险之间的联系。
IF 2.2 4区 医学 Q3 ONCOLOGY Pub Date : 2025-04-01 Epub Date: 2024-12-11 DOI: 10.1007/s10552-024-01946-5
Eman A Toraih, Mohammad H Hussein, Manal S Malik, Alaa N Malik, Emad Kandil, Manal S Fawzy

Purpose: Clear patient communication with the physician is an integral aspect of cancer treatment and successful health outcomes. Previous research has shown improved cancer screening in cases of patient navigator assistance to limited English proficient patients, but no research has analyzed the relationship between language isolation and cancer incidence rates in the United States.

Methods: Using state-level data from the United States Census Bureau and the National Cancer Institute, we analyzed the correlations between language isolation and age-adjusted incidence rates across 19 different invasive cancers.

Results: A complex relationship between language isolation and cancer incidence rates was found. States such as California, New York, Texas, and New Jersey show high language isolate prevalence and elevated cancer incidence rates. Cancer subtype incidence rates varied between states, indicating the multifactorial importance of lifestyle, genetics, and environment in cancer. California had the highest language isolation ranking of 8.5% and elevated rates of ovarian (10.4/100,000) and stomach (9.1/100,000) cancers. New York, with the second-highest language isolation ranking of 7.6%, manifests a pronounced prevalence of ovarian (11.3/100,000) and stomach (10.9/100,000) cancers. Overall, positive correlations were observed between language isolation and ovarian/stomach cancers, while negative correlations were found with lung, kidney, melanoma, and colorectal cancers.

Conclusion: This study emphasizes the need to address language barriers and other social determinants of health in cancer prevention/control. Targeted interventions, such as culturally appropriate education, increased access to linguistically and culturally appropriate cancer screening, and language lessons, are crucial in improving health outcomes in linguistically diverse communities.

目的:与医生明确的患者沟通是癌症治疗和成功健康结果的一个组成部分。先前的研究表明,在对英语水平有限的患者进行患者导航员辅助的情况下,癌症筛查得到了改善,但没有研究分析了美国语言隔离与癌症发病率之间的关系。方法:利用美国人口普查局和美国国家癌症研究所的州级数据,我们分析了19种不同侵袭性癌症中语言隔离与年龄调整后发病率之间的相关性。结果:语言隔离与癌症发病率之间存在复杂的关系。在加利福尼亚、纽约、德克萨斯和新泽西等州,语言隔离率很高,癌症发病率也很高。癌症亚型发病率在各州之间存在差异,这表明生活方式、遗传和环境在癌症中的多因素重要性。加州的语言隔离率最高,为8.5%,卵巢癌(10.4/10万)和胃癌(9.1/10万)的发病率也较高。纽约的语言隔离率排名第二,为7.6%,卵巢癌(11.3/10万)和胃癌(10.9/10万)的发病率很高。总体而言,语言隔离与卵巢癌/胃癌呈正相关,而与肺癌、肾癌、黑色素瘤和结直肠癌呈负相关。结论:本研究强调了在癌症预防/控制中解决语言障碍和其他健康社会决定因素的必要性。有针对性的干预措施,如文化上适当的教育、增加获得语言和文化上适当的癌症筛查的机会以及语言课程,对于改善语言多样化社区的健康结果至关重要。
{"title":"Unraveling the link between language barriers and cancer risk.","authors":"Eman A Toraih, Mohammad H Hussein, Manal S Malik, Alaa N Malik, Emad Kandil, Manal S Fawzy","doi":"10.1007/s10552-024-01946-5","DOIUrl":"10.1007/s10552-024-01946-5","url":null,"abstract":"<p><strong>Purpose: </strong>Clear patient communication with the physician is an integral aspect of cancer treatment and successful health outcomes. Previous research has shown improved cancer screening in cases of patient navigator assistance to limited English proficient patients, but no research has analyzed the relationship between language isolation and cancer incidence rates in the United States.</p><p><strong>Methods: </strong>Using state-level data from the United States Census Bureau and the National Cancer Institute, we analyzed the correlations between language isolation and age-adjusted incidence rates across 19 different invasive cancers.</p><p><strong>Results: </strong>A complex relationship between language isolation and cancer incidence rates was found. States such as California, New York, Texas, and New Jersey show high language isolate prevalence and elevated cancer incidence rates. Cancer subtype incidence rates varied between states, indicating the multifactorial importance of lifestyle, genetics, and environment in cancer. California had the highest language isolation ranking of 8.5% and elevated rates of ovarian (10.4/100,000) and stomach (9.1/100,000) cancers. New York, with the second-highest language isolation ranking of 7.6%, manifests a pronounced prevalence of ovarian (11.3/100,000) and stomach (10.9/100,000) cancers. Overall, positive correlations were observed between language isolation and ovarian/stomach cancers, while negative correlations were found with lung, kidney, melanoma, and colorectal cancers.</p><p><strong>Conclusion: </strong>This study emphasizes the need to address language barriers and other social determinants of health in cancer prevention/control. Targeted interventions, such as culturally appropriate education, increased access to linguistically and culturally appropriate cancer screening, and language lessons, are crucial in improving health outcomes in linguistically diverse communities.</p>","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":"399-407"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of smokeless tobacco on cancer incidence and mortality: a global systematic review and meta-analysis. 无烟烟草对癌症发病率和死亡率的影响:一项全球系统综述和荟萃分析。
IF 2.2 4区 医学 Q3 ONCOLOGY Pub Date : 2025-04-01 Epub Date: 2024-12-24 DOI: 10.1007/s10552-024-01933-w
Zin Wai Htay, Aliza K C Bhandari, Rokshana Parvin, Sarah Krull Abe

Introduction: The prevalence of smokeless tobacco consumption remains high despite policies on reduction interventions. This study aims to quantify the associations between smokeless tobacco use with cancer incidence and mortality globally.

Methods: We conducted a systematic review and meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and PROSPERO protocol (ID: CRD42023390468). A comprehensive literature search was performed using PubMed, Web of Science, and Scopus databases, covering the period from January 1, 2000, to February 28, 2023. We included peer-reviewed observational studies, specifically case-control and cohort studies, where smokeless tobacco use was the primary exposure and cancer incidence, or mortality were the main outcomes. Three independent reviewers screened titles, abstracts, and full texts, and extracted data from the included studies. Risk of bias was assessed by the same three reviewers. Any disagreements were resolved through discussion with a fourth reviewer. We performed random-effects meta-analyses and assessed heterogeneity and publication bias to ensure the robustness of our findings.

Results: Of the 3,611 articles identified, 80 were included in the final analysis. Increased risks were observed for cancer mortality [Risk Ratio (RR) 1.38, 95% Confidence Interval (CI) 1.22-1.56] and incidence [RR 1.17, 95% CI 1.08-1.27]. The specific cancer sites with increased mortality risk included head and neck cancers, as well as stomach cancer. For cancer incidence, associations were observed with head and neck, oral, esophageal, stomach, and pancreatic cancers. Significant heterogeneity (I2 statistic 65% to 90%) was observed among most cancer outcomes.

Conclusion: Our study found significant associations between smokeless tobacco use and cancer incidence and mortality. Targeted policy interventions, such as stricter regulations on smokeless tobacco use, are recommended to reduce its consumption and mitigate the associated cancer risks.

导言:尽管有减少干预措施的政策,但无烟烟草消费的流行率仍然很高。本研究旨在量化全球无烟烟草使用与癌症发病率和死亡率之间的关系。方法:我们按照系统评价和荟萃分析首选报告项目(PRISMA)指南和PROSPERO协议(ID: CRD42023390468)进行了系统评价和荟萃分析。使用PubMed、Web of Science和Scopus数据库进行全面的文献检索,检索时间为2000年1月1日至2023年2月28日。我们纳入了同行评议的观察性研究,特别是病例对照和队列研究,其中无烟烟草使用是主要暴露,癌症发病率或死亡率是主要结果。三位独立审稿人筛选标题、摘要和全文,并从纳入的研究中提取数据。偏倚风险由相同的三位审稿人评估。任何分歧都通过与第四位审稿人讨论来解决。我们进行了随机效应荟萃分析,并评估了异质性和发表偏倚,以确保我们研究结果的稳健性。结果:在鉴定的3,611篇文章中,有80篇被纳入最终分析。癌症死亡率[危险比(RR) 1.38, 95%可信区间(CI) 1.22-1.56]和发病率[RR 1.17, 95%可信区间(CI) 1.08-1.27]增加。死亡风险增加的特定癌症部位包括头颈癌和胃癌。癌症发病率与头颈癌、口腔癌、食管癌、胃癌和胰腺癌有关。在大多数癌症结局中观察到显著的异质性(I2统计值为65%至90%)。结论:我们的研究发现无烟烟草使用与癌症发病率和死亡率之间存在显著关联。建议采取有针对性的政策干预措施,例如对无烟烟草的使用实施更严格的规定,以减少其消费并减轻相关的癌症风险。
{"title":"Effects of smokeless tobacco on cancer incidence and mortality: a global systematic review and meta-analysis.","authors":"Zin Wai Htay, Aliza K C Bhandari, Rokshana Parvin, Sarah Krull Abe","doi":"10.1007/s10552-024-01933-w","DOIUrl":"10.1007/s10552-024-01933-w","url":null,"abstract":"<p><strong>Introduction: </strong>The prevalence of smokeless tobacco consumption remains high despite policies on reduction interventions. This study aims to quantify the associations between smokeless tobacco use with cancer incidence and mortality globally.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and PROSPERO protocol (ID: CRD42023390468). A comprehensive literature search was performed using PubMed, Web of Science, and Scopus databases, covering the period from January 1, 2000, to February 28, 2023. We included peer-reviewed observational studies, specifically case-control and cohort studies, where smokeless tobacco use was the primary exposure and cancer incidence, or mortality were the main outcomes. Three independent reviewers screened titles, abstracts, and full texts, and extracted data from the included studies. Risk of bias was assessed by the same three reviewers. Any disagreements were resolved through discussion with a fourth reviewer. We performed random-effects meta-analyses and assessed heterogeneity and publication bias to ensure the robustness of our findings.</p><p><strong>Results: </strong>Of the 3,611 articles identified, 80 were included in the final analysis. Increased risks were observed for cancer mortality [Risk Ratio (RR) 1.38, 95% Confidence Interval (CI) 1.22-1.56] and incidence [RR 1.17, 95% CI 1.08-1.27]. The specific cancer sites with increased mortality risk included head and neck cancers, as well as stomach cancer. For cancer incidence, associations were observed with head and neck, oral, esophageal, stomach, and pancreatic cancers. Significant heterogeneity (I<sup>2</sup> statistic 65% to 90%) was observed among most cancer outcomes.</p><p><strong>Conclusion: </strong>Our study found significant associations between smokeless tobacco use and cancer incidence and mortality. Targeted policy interventions, such as stricter regulations on smokeless tobacco use, are recommended to reduce its consumption and mitigate the associated cancer risks.</p>","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":"321-352"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Misclassification of second primary and recurrent breast cancer in the surveillance epidemiology and end results registry. 监测流行病学和最终结果登记处对第二原发性和复发性乳腺癌的错误分类。
IF 2.2 4区 医学 Q3 ONCOLOGY Pub Date : 2025-04-01 Epub Date: 2024-12-19 DOI: 10.1007/s10552-024-01944-7
Sarah C Van Alsten, Isaiah Zipple, Benjamin C Calhoun, Melissa A Troester

The Surveillance Epidemiology and End Results (SEER) registry incorporates laterality, histology, latency, and topography to identify second primary breast cancers. Contralateral tumors are classified as second primaries, but ipsilaterals are subject to additional inclusion criteria that increase specificity but may induce biases. It is important to understand how classification methods affect accuracy of second tumor classification. We collected estrogen, progesterone, and human epidermal growth factor receptor 2 (ER, PR, Her2) status for 11,838 contralateral and 5,371 ipsilateral metachronous secondary tumors and estimated concordance odds ratios (cORs) to evaluate receptor dependence (the tendency for tumors to share receptor status) by laterality. If only second primaries are included, receptor dependence should be similar for contralateral and ipsilateral tumors. Thus, we compared ratios of cORs as a measure of inaccuracy. Cases who met ipsilateral second primary criteria were younger and had less aggressive primary tumor characteristics compared to contralateral tumors. Time to secondary tumors was (by definition) longer for ipsilaterals than contralaterals, especially among ER + primaries. Overall and in multiple strata, ipsilateral tumors showed higher receptor dependence than contralateral tumors (ratios of cORs > 1), suggesting some SEER-included ipsilaterals are recurrences. SEER multiple primary criteria increase specificity, but remain inaccurate and may lack sensitivity. The dearth of early occurring ipsilateral tumors (by definition), coupled with high observed receptor dependence among ipsilaterals, suggests important inaccuracies. Datasets that allow comparison of pathologist- and SEER-classification to true multi-marker genomic dependence are needed to understand inaccuracies induced by SEER definitions.

监测流行病学和最终结果(SEER)登记包括侧发性、组织学、潜伏期和地形,以确定第二原发性乳腺癌。对侧肿瘤被归类为第二原发肿瘤,但同侧肿瘤需要额外的纳入标准,这增加了特异性,但可能会引起偏差。了解分类方法如何影响肿瘤二次分类的准确性是很重要的。我们收集了11,838例对侧和5,371例同侧异时性继发性肿瘤的雌激素、孕激素和人表皮生长因子受体2 (ER, PR, Her2)状态,并估计了一致性优势比(cORs)来评估受体依赖(肿瘤共享受体状态的趋势)。如果只包括第二原发肿瘤,对侧和同侧肿瘤的受体依赖性应该相似。因此,我们比较了cORs的比率作为不准确性的衡量标准。与对侧肿瘤相比,符合同侧第二原发标准的病例更年轻,原发肿瘤的侵袭性更小。同侧继发肿瘤的时间(根据定义)比对侧更长,尤其是ER +原发灶。总的来说,在多个层面上,同侧肿瘤比对侧肿瘤表现出更高的受体依赖性(cORs比为1),表明一些包含seer的同侧肿瘤是复发。SEER多重主要标准增加了特异性,但仍然不准确,可能缺乏敏感性。早期发生的同侧肿瘤(根据定义)的缺乏,加上同侧高度观察到的受体依赖性,表明了重要的不准确性。需要将病理学家和SEER分类与真正的多标记基因组依赖性进行比较的数据集,以了解由SEER定义引起的不准确性。
{"title":"Misclassification of second primary and recurrent breast cancer in the surveillance epidemiology and end results registry.","authors":"Sarah C Van Alsten, Isaiah Zipple, Benjamin C Calhoun, Melissa A Troester","doi":"10.1007/s10552-024-01944-7","DOIUrl":"10.1007/s10552-024-01944-7","url":null,"abstract":"<p><p>The Surveillance Epidemiology and End Results (SEER) registry incorporates laterality, histology, latency, and topography to identify second primary breast cancers. Contralateral tumors are classified as second primaries, but ipsilaterals are subject to additional inclusion criteria that increase specificity but may induce biases. It is important to understand how classification methods affect accuracy of second tumor classification. We collected estrogen, progesterone, and human epidermal growth factor receptor 2 (ER, PR, Her2) status for 11,838 contralateral and 5,371 ipsilateral metachronous secondary tumors and estimated concordance odds ratios (cORs) to evaluate receptor dependence (the tendency for tumors to share receptor status) by laterality. If only second primaries are included, receptor dependence should be similar for contralateral and ipsilateral tumors. Thus, we compared ratios of cORs as a measure of inaccuracy. Cases who met ipsilateral second primary criteria were younger and had less aggressive primary tumor characteristics compared to contralateral tumors. Time to secondary tumors was (by definition) longer for ipsilaterals than contralaterals, especially among ER + primaries. Overall and in multiple strata, ipsilateral tumors showed higher receptor dependence than contralateral tumors (ratios of cORs > 1), suggesting some SEER-included ipsilaterals are recurrences. SEER multiple primary criteria increase specificity, but remain inaccurate and may lack sensitivity. The dearth of early occurring ipsilateral tumors (by definition), coupled with high observed receptor dependence among ipsilaterals, suggests important inaccuracies. Datasets that allow comparison of pathologist- and SEER-classification to true multi-marker genomic dependence are needed to understand inaccuracies induced by SEER definitions.</p>","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":"421-432"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11981851/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Empowering cancer prevention with AI: unlocking new frontiers in prediction, diagnosis, and intervention. 利用人工智能增强癌症预防能力:开辟预测、诊断和干预的新领域。
IF 2.2 4区 医学 Q3 ONCOLOGY Pub Date : 2025-04-01 Epub Date: 2024-12-13 DOI: 10.1007/s10552-024-01942-9
Marianna-Foteini Dafni, Mohamed Shih, Agnes Zanotto Manoel, Mohamed Yousif Elamin Yousif, Stavroula Spathi, Chorya Harshal, Gaurang Bhatt, Swarali Yatin Chodnekar, Nicholas Stam Chune, Warda Rasool, Tungki Pratama Umar, Dimitrios C Moustakas, Robert Achkar, Harendra Kumar, Suhaila Naz, Luis M Acuña-Chavez, Konstantinos Evgenikos, Shaina Gulraiz, Eslam Salih Musa Ali, Amna Elaagib, Innocent H Peter Uggh

Artificial intelligence is rapidly changing our world at an exponential rate and its transformative power has extensively reached important sectors like healthcare. In the fight against cancer, AI proved to be a novel and powerful tool, offering new hope for prevention and early detection. In this review, we will comprehensively explore the medical applications of AI, including early cancer detection through pathological and imaging analysis, risk stratification, patient triage, and the development of personalized prevention approaches. However, despite the successful impact AI has contributed to, we will also discuss the myriad of challenges that we have faced so far toward optimal AI implementation. There are problems when it comes to the best way in which we can use AI systemically. Having the correct data that can be understood easily must remain one of the most significant concerns in all its uses including sharing information. Another challenge that exists is how to interpret AI models because they are too complicated for people to follow through examples used in their developments which may affect trust, especially among medical professionals. Other considerations like data privacy, algorithm bias, and equitable access to AI tools have also arisen. Finally, we will evaluate possible future directions for this promising field that highlight AI's capacity to transform preventative cancer care.

人工智能正以指数级的速度迅速改变着我们的世界,其变革力量已广泛渗透到医疗保健等重要领域。在抗击癌症的斗争中,人工智能被证明是一种新颖而强大的工具,为预防和早期检测带来了新的希望。在这篇综述中,我们将全面探讨人工智能在医疗领域的应用,包括通过病理和成像分析进行早期癌症检测、风险分层、患者分流以及开发个性化预防方法。然而,尽管人工智能已经产生了成功的影响,我们也将讨论迄今为止我们在实现最佳人工智能方面所面临的无数挑战。我们在系统地使用人工智能的最佳方式方面存在问题。在包括信息共享在内的所有人工智能应用中,拥有易于理解的正确数据仍然是最重要的问题之一。另一个挑战是如何解释人工智能模型,因为这些模型过于复杂,人们无法通过模型开发中使用的示例来理解,这可能会影响信任度,尤其是在医疗专业人士之间。其他考虑因素如数据隐私、算法偏差和公平使用人工智能工具等也已出现。最后,我们将评估这一前景广阔的领域未来可能的发展方向,以突出人工智能改变预防性癌症护理的能力。
{"title":"Empowering cancer prevention with AI: unlocking new frontiers in prediction, diagnosis, and intervention.","authors":"Marianna-Foteini Dafni, Mohamed Shih, Agnes Zanotto Manoel, Mohamed Yousif Elamin Yousif, Stavroula Spathi, Chorya Harshal, Gaurang Bhatt, Swarali Yatin Chodnekar, Nicholas Stam Chune, Warda Rasool, Tungki Pratama Umar, Dimitrios C Moustakas, Robert Achkar, Harendra Kumar, Suhaila Naz, Luis M Acuña-Chavez, Konstantinos Evgenikos, Shaina Gulraiz, Eslam Salih Musa Ali, Amna Elaagib, Innocent H Peter Uggh","doi":"10.1007/s10552-024-01942-9","DOIUrl":"10.1007/s10552-024-01942-9","url":null,"abstract":"<p><p>Artificial intelligence is rapidly changing our world at an exponential rate and its transformative power has extensively reached important sectors like healthcare. In the fight against cancer, AI proved to be a novel and powerful tool, offering new hope for prevention and early detection. In this review, we will comprehensively explore the medical applications of AI, including early cancer detection through pathological and imaging analysis, risk stratification, patient triage, and the development of personalized prevention approaches. However, despite the successful impact AI has contributed to, we will also discuss the myriad of challenges that we have faced so far toward optimal AI implementation. There are problems when it comes to the best way in which we can use AI systemically. Having the correct data that can be understood easily must remain one of the most significant concerns in all its uses including sharing information. Another challenge that exists is how to interpret AI models because they are too complicated for people to follow through examples used in their developments which may affect trust, especially among medical professionals. Other considerations like data privacy, algorithm bias, and equitable access to AI tools have also arisen. Finally, we will evaluate possible future directions for this promising field that highlight AI's capacity to transform preventative cancer care.</p>","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":"353-367"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142821935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breast cancer screening needs assessment in 19 Northern California counties: geography, poverty, and racial/ethnic identity composition. 北加州19个县的乳腺癌筛查需求评估:地理、贫困和种族/民族身份构成
IF 2.2 4区 医学 Q3 ONCOLOGY Pub Date : 2025-04-01 Epub Date: 2024-12-01 DOI: 10.1007/s10552-024-01943-8
Brittany L Morgan Bustamante, Diana Miglioretti, Theresa Keegan, Eric Stewart, Anshu Shrestha, Nuen Tsang Yang, Rosemary D Cress, Luis Carvajal-Carmona, Julie Dang, Laura Fejerman

Purpose: To describe the area-level rate of breast cancers, the percentage of early-stage diagnoses (stage I-IIa), and associations between area-level measures of poverty, racial/ethnic composition, primary care shortage, and urban/rural/frontier status for the UC Davis Comprehensive Cancer Center (UCDCCC) catchment area.

Methods: Using data from the SEER Cancer Registry of Greater California (2014-2018) and the California Department of Health Care Access and Information Medical Service Study Area, we conducted an ecological study in the UCDCCC catchment area to identify geographies that need screening interventions and their demographic characteristics.

Results: The higher the percentage of the population identifying as Hispanic/Latino/Latinx, and the higher the percentage of the population below the 100% poverty level, the lower the odds of being diagnosed at an early-stage (OR = 0.98, 95% CI 0.96-0.99 and OR = 0.96, 95% CI 0.93-0.99, respectively). The association with poverty level was attenuated in the multivariable model when the Hispanic/Latino/Latinx population percentage was added. Several California counties had high poverty levels and differences in cancer stage distribution between racial/ethnic category groups. For all individuals combined, 65% was the lowest proportion of early-stage diagnoses for any geography. However, when stratified by racial/ethnic category, 11 geographies were below 65% for Hispanic/Latino/Latinx individuals, six for non-Hispanic Asian and Pacific Islander individuals, and seven for non-Hispanic African American/Black individuals, in contrast to one for non-Hispanic White individuals.

Conclusions: Areas with lower percentages of breast cancers diagnosed at an early-stage were characterized by high levels of poverty. Variation in the proportion of early-stage diagnosis was also observed by race/ethnicity where the proportion of Hispanic/Latino/Latinx individuals was associated with fewer early-stage diagnoses.

Impact: Results will inform the implementation of the UCDCCC mobile cancer prevention and early detection program, providing specific locations and populations to prioritize for tailored outreach, education, and screening.

目的:描述加州大学戴维斯分校综合癌症中心(UCDCCC)集水区乳腺癌的区域发病率、早期诊断(I-IIa期)的百分比,以及区域贫困、种族/民族构成、初级保健短缺和城市/农村/边境状况之间的关系。方法:利用大加利福尼亚州SEER癌症登记处(2014-2018)和加利福尼亚州卫生保健获取和信息医疗服务研究区的数据,我们在UCDCCC集水区进行了一项生态研究,以确定需要筛查干预的地理区域及其人口统计学特征。结果:西班牙裔/拉丁裔/拉丁裔人口比例越高,低于100%贫困水平的人口比例越高,早期诊断的几率越低(OR = 0.98, 95% CI 0.96-0.99, OR = 0.96, 95% CI 0.93-0.99)。在多变量模型中,当加入西班牙裔/拉丁裔/拉丁裔人口百分比时,与贫困水平的关联减弱。加州几个县的贫困率很高,不同种族/民族的癌症分期分布也存在差异。所有个体加起来,65%是所有地区早期诊断比例最低的。然而,当按种族/民族类别分层时,11个地区的西班牙裔/拉丁裔/拉丁裔个体的比例低于65%,6个地区的非西班牙裔亚裔和太平洋岛民个体的比例低于65%,7个地区的非西班牙裔美国人/黑人个体的比例低于65%,而非西班牙裔白人个体的比例为1个。结论:早期乳腺癌确诊率较低的地区,其特点是贫困程度较高。早期诊断比例的差异还观察到种族/民族的差异,其中西班牙裔/拉丁裔/拉丁裔个体的比例与早期诊断较少相关。影响:结果将为UCDCCC移动癌症预防和早期检测项目的实施提供信息,提供具体地点和人群,优先进行量身定制的推广、教育和筛查。
{"title":"Breast cancer screening needs assessment in 19 Northern California counties: geography, poverty, and racial/ethnic identity composition.","authors":"Brittany L Morgan Bustamante, Diana Miglioretti, Theresa Keegan, Eric Stewart, Anshu Shrestha, Nuen Tsang Yang, Rosemary D Cress, Luis Carvajal-Carmona, Julie Dang, Laura Fejerman","doi":"10.1007/s10552-024-01943-8","DOIUrl":"10.1007/s10552-024-01943-8","url":null,"abstract":"<p><strong>Purpose: </strong>To describe the area-level rate of breast cancers, the percentage of early-stage diagnoses (stage I-IIa), and associations between area-level measures of poverty, racial/ethnic composition, primary care shortage, and urban/rural/frontier status for the UC Davis Comprehensive Cancer Center (UCDCCC) catchment area.</p><p><strong>Methods: </strong>Using data from the SEER Cancer Registry of Greater California (2014-2018) and the California Department of Health Care Access and Information Medical Service Study Area, we conducted an ecological study in the UCDCCC catchment area to identify geographies that need screening interventions and their demographic characteristics.</p><p><strong>Results: </strong>The higher the percentage of the population identifying as Hispanic/Latino/Latinx, and the higher the percentage of the population below the 100% poverty level, the lower the odds of being diagnosed at an early-stage (OR = 0.98, 95% CI 0.96-0.99 and OR = 0.96, 95% CI 0.93-0.99, respectively). The association with poverty level was attenuated in the multivariable model when the Hispanic/Latino/Latinx population percentage was added. Several California counties had high poverty levels and differences in cancer stage distribution between racial/ethnic category groups. For all individuals combined, 65% was the lowest proportion of early-stage diagnoses for any geography. However, when stratified by racial/ethnic category, 11 geographies were below 65% for Hispanic/Latino/Latinx individuals, six for non-Hispanic Asian and Pacific Islander individuals, and seven for non-Hispanic African American/Black individuals, in contrast to one for non-Hispanic White individuals.</p><p><strong>Conclusions: </strong>Areas with lower percentages of breast cancers diagnosed at an early-stage were characterized by high levels of poverty. Variation in the proportion of early-stage diagnosis was also observed by race/ethnicity where the proportion of Hispanic/Latino/Latinx individuals was associated with fewer early-stage diagnoses.</p><p><strong>Impact: </strong>Results will inform the implementation of the UCDCCC mobile cancer prevention and early detection program, providing specific locations and populations to prioritize for tailored outreach, education, and screening.</p>","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":"369-377"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utilization and outcomes of serial cervical cancer screening in a National Breast and Cervical Cancer Early Detection Program (NBCCEDP) in a non-Medicaid expansion state. 国家乳腺癌和宫颈癌早期检测计划(NBCCEDP)在非医疗补助扩张状态下的一系列宫颈癌筛查的使用和结果
IF 2.2 4区 医学 Q3 ONCOLOGY Pub Date : 2025-04-01 Epub Date: 2024-12-16 DOI: 10.1007/s10552-024-01948-3
Rubina Ratnaparkhi, Ahmed Ismail, Hope Krebill, Ian Cook, Melissa Javellana, Andrea Jewell, Lori Spoozak, Amanda Emerson, Megha Ramaswamy, Elizabeth Calhoun, Dinesh Pal Mudaranthakam

Purpose: Since 1990, the Centers for Disease Control and Prevention's National Breast and Cervical Cancer Early Detection Program (NBCCEDP) has offered free cervical cancer screening to low-income, uninsured patients, increasing single time point screening and early detection rates. Little is known about NBCCEDP's longitudinal effectiveness. The objective of this study was to assess utilization of Kansas's NBCCEDP, early detection works (EDW) for one-time versus serial screening and compare rates of cervical dysplasia between groups.

Methods: A retrospective cohort study was conducted among patients who received cervical cancer screening through EDW from 2001 to 2021. Demographic factors, Papanicolaou (Pap) test, and human papillomavirus (HPV) results were compared between patients with one screening versus multiple. Descriptive statistics were performed.

Results: From 2014 to 2021, 3.71-7.06% of eligible patients completed screening through EDW annually. 17.4% of 58,582 eligible patients were up-to-date with screening in 2020. Rural patients and those under age forty were less likely to have EDW screening. Of 43,916 ever-screened patients, 14,638 (33.3%) received multiple screenings. 77% of patients did not have HPV testing; rates were lower in serially screened patients. Cervical dysplasia rates differed minimally between groups.

Conclusion: Despite screening 24,017 patients over 7 years, EDW maintains up-to-date screening for under one-fourth of eligible Kansans. Young and rural patients less frequently access EDW. HPV testing is underutilized, which limits the negative predictive value of screening. Serial screening is largely used by low-risk patients currently. Identification and prioritization of serial screening in high risk could increase program impact.

目的:自1990年以来,疾病控制和预防中心的国家乳腺癌和宫颈癌早期检测计划(NBCCEDP)向低收入、无保险的患者提供免费的宫颈癌筛查,提高了单时间点筛查和早期检出率。对NBCCEDP的纵向有效性知之甚少。本研究的目的是评估堪萨斯州的NBCCEDP,早期检测工作(EDW)用于一次性和系列筛查的利用率,并比较两组之间宫颈发育不良的发生率。方法:对2001年至2021年通过EDW进行宫颈癌筛查的患者进行回顾性队列研究。人口统计学因素、巴氏涂片(Pap)试验和人乳头瘤病毒(HPV)结果在一次筛查和多次筛查的患者之间进行比较。进行描述性统计。结果:2014 - 2021年,每年有3.71-7.06%的符合条件的患者通过EDW完成筛查。在58,582名符合条件的患者中,有17.4%在2020年进行了最新筛查。农村患者和40岁以下的患者不太可能进行EDW筛查。在43,916例接受过筛查的患者中,14,638例(33.3%)接受了多次筛查。77%的患者未进行HPV检测;在连续筛查的患者中,这一比例较低。宫颈发育不良发生率组间差异极小。结论:尽管在7年的时间里对24017名患者进行了筛查,EDW对不到四分之一的合格堪萨斯人进行了最新的筛查。年轻和农村患者较少获得EDW。HPV检测未得到充分利用,这限制了筛查的阴性预测价值。目前,系列筛查主要用于低危患者。识别和优先考虑高风险的系列筛查可以增加项目的影响。
{"title":"Utilization and outcomes of serial cervical cancer screening in a National Breast and Cervical Cancer Early Detection Program (NBCCEDP) in a non-Medicaid expansion state.","authors":"Rubina Ratnaparkhi, Ahmed Ismail, Hope Krebill, Ian Cook, Melissa Javellana, Andrea Jewell, Lori Spoozak, Amanda Emerson, Megha Ramaswamy, Elizabeth Calhoun, Dinesh Pal Mudaranthakam","doi":"10.1007/s10552-024-01948-3","DOIUrl":"10.1007/s10552-024-01948-3","url":null,"abstract":"<p><strong>Purpose: </strong>Since 1990, the Centers for Disease Control and Prevention's National Breast and Cervical Cancer Early Detection Program (NBCCEDP) has offered free cervical cancer screening to low-income, uninsured patients, increasing single time point screening and early detection rates. Little is known about NBCCEDP's longitudinal effectiveness. The objective of this study was to assess utilization of Kansas's NBCCEDP, early detection works (EDW) for one-time versus serial screening and compare rates of cervical dysplasia between groups.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted among patients who received cervical cancer screening through EDW from 2001 to 2021. Demographic factors, Papanicolaou (Pap) test, and human papillomavirus (HPV) results were compared between patients with one screening versus multiple. Descriptive statistics were performed.</p><p><strong>Results: </strong>From 2014 to 2021, 3.71-7.06% of eligible patients completed screening through EDW annually. 17.4% of 58,582 eligible patients were up-to-date with screening in 2020. Rural patients and those under age forty were less likely to have EDW screening. Of 43,916 ever-screened patients, 14,638 (33.3%) received multiple screenings. 77% of patients did not have HPV testing; rates were lower in serially screened patients. Cervical dysplasia rates differed minimally between groups.</p><p><strong>Conclusion: </strong>Despite screening 24,017 patients over 7 years, EDW maintains up-to-date screening for under one-fourth of eligible Kansans. Young and rural patients less frequently access EDW. HPV testing is underutilized, which limits the negative predictive value of screening. Serial screening is largely used by low-risk patients currently. Identification and prioritization of serial screening in high risk could increase program impact.</p>","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":"409-420"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11981844/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142833907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of outcomes by race among a population-based matched sample of multiple myeloma patients. 多发性骨髓瘤患者人群匹配样本中不同种族结果的比较。
IF 2.2 4区 医学 Q3 ONCOLOGY Pub Date : 2025-04-01 Epub Date: 2024-11-26 DOI: 10.1007/s10552-024-01938-5
Breanna B Greteman, Michael H Tomasson, Amanda R Kahl, Madison M Wahlen, Melissa L Bates, Christopher Strouse, Mary E Charlton

Purpose: It is important to understand racial inequities in multiple myeloma treatment and survival, particularly in the Midwest where clear differences exist in cancer incidence and mortality. Since age and geographic location can greatly impact treatment and prognosis, matching patients on these characteristics can help identify reasons for outcome differences.

Methods: Retrospective data from the Iowa Cancer Registry's Surveillance, Epidemiology, and End Results database were analyzed for adult patients diagnosed with first primary MM between 1/1/2010-12/31/2019. Matching procedures matched up to 4 White patients with each Black patient on age and city of residence. Demographic characteristics were compared, and Cox proportional hazards models were built to compare survival.

Results: There were 1,845 patients in our overall sample, of which 85 were Black and 1,760 were White. There were 321 patients (74 Black, 247 White) that were matched. Black patients in the overall sample had decreased hazard for MM-specific death compared to White (HR = 0.50, 95% CI (0.43, 0.78)) when controlling for covariates. The decrease in MM-specific death in black patients was not statistically significant compared to matched controls (HR = 0.72, 95% CI (0.41, 1.27)). Treatment differences were not observed for either sample.

Conclusion: We found that, despite large racial differences in MM incidence and mortality in Iowa, there are no survival differences when matched on age and city of residence. These data fail to detect large barriers to myeloma treatment in Iowa, and are useful for formulating potential screening and prevention strategies. Future research should also assess results in different geographic areas, investigate survival among older White patients in rural areas, and investigate other potential reasons for mortality differences between Black and White MM patients such as specific treatments received.

目的:了解多发性骨髓瘤治疗和生存方面的种族不平等现象非常重要,尤其是在癌症发病率和死亡率存在明显差异的中西部地区。由于年龄和地理位置会对治疗和预后产生很大影响,因此将患者的这些特征进行匹配有助于找出结果差异的原因:方法:分析了爱荷华州癌症登记处的监测、流行病学和最终结果数据库中的回顾性数据,这些数据针对的是 2010 年 1 月 1 日至 2019 年 12 月 31 日期间诊断为初诊 MM 的成年患者。匹配程序根据年龄和居住城市为每名黑人患者匹配了最多 4 名白人患者。比较了人口统计学特征,并建立了Cox比例危险模型来比较生存率:总样本中有 1,845 名患者,其中黑人 85 人,白人 1,760 人。有 321 名患者(74 名黑人,247 名白人)进行了配对。在控制协变量的情况下,总体样本中的黑人患者与白人患者相比,MM特异性死亡的风险降低(HR = 0.50,95% CI (0.43,0.78))。与匹配的对照组相比,黑人患者MM特异性死亡风险的降低在统计学上并不显著(HR = 0.72,95% CI (0.41,1.27))。两个样本均未观察到治疗差异:我们发现,尽管爱荷华州在 MM 发病率和死亡率方面存在巨大的种族差异,但在年龄和居住城市匹配的情况下,并不存在生存差异。这些数据未能发现爱荷华州骨髓瘤治疗的巨大障碍,但对制定潜在的筛查和预防策略很有帮助。未来的研究还应评估不同地理区域的结果,调查农村地区老年白人患者的存活率,并调查造成黑人和白人骨髓瘤患者死亡率差异的其他潜在原因,如接受的特定治疗。
{"title":"Comparison of outcomes by race among a population-based matched sample of multiple myeloma patients.","authors":"Breanna B Greteman, Michael H Tomasson, Amanda R Kahl, Madison M Wahlen, Melissa L Bates, Christopher Strouse, Mary E Charlton","doi":"10.1007/s10552-024-01938-5","DOIUrl":"10.1007/s10552-024-01938-5","url":null,"abstract":"<p><strong>Purpose: </strong>It is important to understand racial inequities in multiple myeloma treatment and survival, particularly in the Midwest where clear differences exist in cancer incidence and mortality. Since age and geographic location can greatly impact treatment and prognosis, matching patients on these characteristics can help identify reasons for outcome differences.</p><p><strong>Methods: </strong>Retrospective data from the Iowa Cancer Registry's Surveillance, Epidemiology, and End Results database were analyzed for adult patients diagnosed with first primary MM between 1/1/2010-12/31/2019. Matching procedures matched up to 4 White patients with each Black patient on age and city of residence. Demographic characteristics were compared, and Cox proportional hazards models were built to compare survival.</p><p><strong>Results: </strong>There were 1,845 patients in our overall sample, of which 85 were Black and 1,760 were White. There were 321 patients (74 Black, 247 White) that were matched. Black patients in the overall sample had decreased hazard for MM-specific death compared to White (HR = 0.50, 95% CI (0.43, 0.78)) when controlling for covariates. The decrease in MM-specific death in black patients was not statistically significant compared to matched controls (HR = 0.72, 95% CI (0.41, 1.27)). Treatment differences were not observed for either sample.</p><p><strong>Conclusion: </strong>We found that, despite large racial differences in MM incidence and mortality in Iowa, there are no survival differences when matched on age and city of residence. These data fail to detect large barriers to myeloma treatment in Iowa, and are useful for formulating potential screening and prevention strategies. Future research should also assess results in different geographic areas, investigate survival among older White patients in rural areas, and investigate other potential reasons for mortality differences between Black and White MM patients such as specific treatments received.</p>","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":"433-442"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An innovative approach to the multidisciplinary treatment of uninsured breast cancer patients. 为未参保的乳腺癌患者提供多学科治疗的创新方法。
IF 2.2 4区 医学 Q3 ONCOLOGY Pub Date : 2025-03-01 Epub Date: 2024-11-26 DOI: 10.1007/s10552-024-01935-8
Jesse N Nodora, Jacqueline A Gilbert, Maria Elena Martinez, Waqas Arslan, Trevin Reyes, John A Dover, Gilbert M Ramos, Ian G Komenaka, Hebert D Hitchon, Ian K Komenaka

Purpose: A significant proportion of many populations remain uninsured. The aim of the study was to assess differences in breast cancer outcomes before and after the implementation of an innovative approach to the multidisciplinary treatment of uninsured breast cancer patients.

Methods: Retrospective review was performed of patients seen at a safety net hospital from January 2000 to December 2020. Beginning July 2006, an innovative approach was implemented to lower patient costs and facilitate care of uninsured patients.

Results: The study included 1,797 patients, 661 patients before the changes (BCS), and 1136 patients after implementation of the new cost saving approach (ACS). The mean age was 53 years. The majority were uninsured (56%) or insured by Medicaid (31%). Only 18% underwent screening mammography. The ACS group had a higher rate of breast conservation (75% vs 47%, p < 0.001). A higher percentage of the ACS group received adjuvant therapy: Chemotherapy (91% vs 70%, p < 0.001), Radiation therapy (91% vs 70%, p < 0.001), and initiated endocrine therapy (87% vs 67%, p < 0.001). After follow-up of 8 years, these changes resulted in lower ipsilateral breast tumor recurrence (2% vs 16%, p < 0.001) and chest wall recurrence (5% versus 8%) and improvement in overall survival (90% vs 81%, p < 0.001).

Conclusion: Peer-reviewed literature is replete of studies documenting disparities in breast cancer treatment. The current study describes a successful cost-limiting method which takes advantage of existing financial assistance programs to improve care in uninsured patients.

目的:在许多人群中,仍有很大一部分人没有参保。本研究旨在评估对未参保乳腺癌患者实施多学科治疗创新方法前后乳腺癌治疗效果的差异:方法:对 2000 年 1 月至 2020 年 12 月期间在一家安全网医院就诊的患者进行回顾性审查。自 2006 年 7 月起,该医院开始实施一种创新方法,以降低患者费用并促进对未参保患者的治疗:研究对象包括 1797 名患者,其中 661 名患者在改革前(BCS),1136 名患者在实施新的成本节约方法后(ACS)。平均年龄为 53 岁。大多数人没有保险(56%)或有医疗补助保险(31%)。只有 18% 的人接受了乳房 X 光筛查。ACS 组保留乳房的比例更高(75% 对 47%,P 结论:ACS 组保留乳房的比例更高,P 结论:ACS 组保留乳房的比例更高:同行评议的文献中不乏记录乳腺癌治疗差异的研究。本研究介绍了一种成功的成本限制方法,该方法利用现有的经济援助计划来改善未参保患者的治疗。
{"title":"An innovative approach to the multidisciplinary treatment of uninsured breast cancer patients.","authors":"Jesse N Nodora, Jacqueline A Gilbert, Maria Elena Martinez, Waqas Arslan, Trevin Reyes, John A Dover, Gilbert M Ramos, Ian G Komenaka, Hebert D Hitchon, Ian K Komenaka","doi":"10.1007/s10552-024-01935-8","DOIUrl":"10.1007/s10552-024-01935-8","url":null,"abstract":"<p><strong>Purpose: </strong>A significant proportion of many populations remain uninsured. The aim of the study was to assess differences in breast cancer outcomes before and after the implementation of an innovative approach to the multidisciplinary treatment of uninsured breast cancer patients.</p><p><strong>Methods: </strong>Retrospective review was performed of patients seen at a safety net hospital from January 2000 to December 2020. Beginning July 2006, an innovative approach was implemented to lower patient costs and facilitate care of uninsured patients.</p><p><strong>Results: </strong>The study included 1,797 patients, 661 patients before the changes (BCS), and 1136 patients after implementation of the new cost saving approach (ACS). The mean age was 53 years. The majority were uninsured (56%) or insured by Medicaid (31%). Only 18% underwent screening mammography. The ACS group had a higher rate of breast conservation (75% vs 47%, p < 0.001). A higher percentage of the ACS group received adjuvant therapy: Chemotherapy (91% vs 70%, p < 0.001), Radiation therapy (91% vs 70%, p < 0.001), and initiated endocrine therapy (87% vs 67%, p < 0.001). After follow-up of 8 years, these changes resulted in lower ipsilateral breast tumor recurrence (2% vs 16%, p < 0.001) and chest wall recurrence (5% versus 8%) and improvement in overall survival (90% vs 81%, p < 0.001).</p><p><strong>Conclusion: </strong>Peer-reviewed literature is replete of studies documenting disparities in breast cancer treatment. The current study describes a successful cost-limiting method which takes advantage of existing financial assistance programs to improve care in uninsured patients.</p>","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":"309-319"},"PeriodicalIF":2.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer Causes & Control
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1